Evidence map›Paper›PMID 33357635›Full record

ReviewIndian heart journal

Opium and cardiovascular health: A devil or an angel?

Pegah Roayaei, Arya Aminorroaya, Ali Vasheghani-Farahani, Alireza Oraii, Saeed Sadeghian, Hamidreza Poorhosseini, Farzad Masoudkabir

Open access · goldAbstract readReview
In one paragraph

Review in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Sonographic features of internal carotid artery in patients with opioid use disorder: Is opium a new risk factor for atherosclerosis of internal carotid artery?Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Pegah RoayaeiCardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: p.roayaei@yahoo.com.
Arya AminorroayaNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran. Electronic address: a-aminorroaya@student.tums.ac.ir.
Ali Vasheghani-FarahaniCardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran; Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: avasheghani@sina.tums.ac.ir.
Alireza OraiiStudents' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran. Electronic address: alirezaoraii@gmail.com.
Saeed SadeghianTehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: ssadeghian@tums.ac.ir.
Hamidreza PoorhosseiniTehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: poorhossenihr@gmail.com.
Farzad MasoudkabirCardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran; Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: farzad.masoudkabir@gmail.com.
Tehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Opioids have the highest rate of illicit drug consumption after cannabis worldwide. Opium, after tobacco, is still the most commonly abused substance in the Middle East. In addition to the ease of availability, one reason for the high consumption of opium in Asian countries might be a traditional belief among Eastern people and even medical staff that opium may have ameliorating effects on cardiovascular diseases (CVDs) as well as diabetes mellitus, hypertension, and dyslipidemia. Over the last decade, many studies have been performed on humans and animals to evaluate the interplay between opium consumption and stable coronary artery disease, acute coronary syndromes, and atherosclerosis. In this review, we conclude that opium consumption should be considered a risk factor for CVDs. Healthy individuals, as well as cardiac and diabetic patients, should be informed and educated about the hazardous effects of opium consumption on cardiovascular and other chronic diseases.

Indexed as

Analgesics, OpioidCardiovascular DiseasesCardiovascular SystemGlobal HealthHumansIncidenceOpiumRisk FactorsAnalgesics, OpioidOpiumAcute coronary syndromeCoronary artery diseaseOpiumPapaverStroke

Identifiers

PMID33357635
PMCPMC7772609
OpenAlexW3094039075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.